APEIRON Biologics commences clinical COVID-19 trial with inhaled APN01

  • Inhalation of APN01 to directly target SARS-CoV-2 virus in respiratory tract, the lung and tissue itself
  • Primary objective is to evaluate safety and tolerability of inhaled APN01
  • Phase 1 trial to enroll about 40 healthy volunteers
  • Additional US Phase 2 trial with intravenous administration of APN01

Press release (EN) | Presseaussendung (DE)